Limitations of tissue microarrays compared with whole tissue sections in survival analysis

Oncology Letters

Volumn 1, Issue 5, 2010, Pages 827-831

  Khouja, M Haysam ^a,c   Baekelandt, Mark ^b   Sarab, Agkha ^c   Nesland, Jahn M ^a   Holm, Ruth ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c UNIVERSITY OF ALEPPO   (Syrian Arab Republic)

Author keywords

Immunohistochemistry; Ki 67; P16; Prognosis; Tissue microarrays; Whole tissue sections

Indexed keywords

KI 67 ANTIGEN; PROTEIN P16;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CORRELATION ANALYSIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY CANCER; PROGNOSIS; PROTEIN EXPRESSION; TISSUE MICROARRAY; TISSUE SECTION;

EID: 77957587461     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol_00000145     Document Type: Article

References (25)

1. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G and Kallioniemi OP: Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4: 844-847, 1998.
2. Mills SE, Fechner RE, Frierson HF, Kempson RL, Wick MR, Dehner LP, Swanson PE and Humphrey PA: Guardians of the wax and the patient. Am J Clin Pathol 104: 365-367, 1995.
3. Camp RL, Charette LA and Rimm DL: Validation of tissue microarray technology in breast carcinoma. Lab Invest 80: 1943-1949, 2000.
4. Tolgay OI, Dolled-Filhart M, D'Aquila TG, Camp RL and Rimm DDL: Tissue microarray-based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptors. Cancer 97: 1841-1848, 2003.
5. Korsching E, Packeisen J, Agelopoulos K, Eisenacher M, Voss R, Isola J, van Diest PJ, Brandt B, Boecker W and Buerger H: Cytogenetic alterations and cytokeratin expression patterns in breast cancer: integrating a new model of breast differentiation into cytogenetic pathways of breast carcinogenesis. Lab Invest 82: 1525-1533, 2002.
6. Griffin MC, Robinson RA and Trask DK: Validation of tissue microarrays using p53 immunohistochemical studies of squamous cell carcinoma of the larynx. Mod Pathol 16: 1181-1188, 2003.
7. Kuwabara S, Ajioka Y, Watanabe H, Hitomi J, Nishikura K and Hatakeyama K: Heterogeneity of p53 mutational status in esophageal squamous cell carcinoma. Jpn J Cancer Res 89: 405-410, 1998.
8. Baisse B, Bouzourene H, Saraga EP, Bosman FT and Benhattar J: Intratumor genetic heterogeneity in advanced human colorectal adenocarcinoma. Int J Cancer 93: 346-352, 2001.
9. Jourdan F, Sebbagh N, Comperat E, Mourra N, Flahault A, Olschwang S, Duval A, Hamelin R and Flejou JF: Tissue microarray technology: validation in colorectal carcinoma and analysis of p53, hMLH1, and hMSH2 immunohistochemical expression. Virchows Arch 443: 115-121, 2003.
10. Gomaa W, Ke Y, Fujii H and Helliwell T: Tissue microarray of head and neck squamous carcinoma: validation of the methodology for the study of cutaneous fatty acid-binding protein, vascular endothelial growth factor, involucrin and Ki-67. Virchows Arch 447: 701-709, 2005.
11. Rosen DG, Huang X, Deavers MT, Malpica A, Silva EG and Liu J: Validation of tissue microarray technology in ovarian carcinoma. Mod Pathol 17: 790-797, 2004.
12. Nocito A, Bubendorf L, Tinner EM, et al: Microarrays of bladder cancer tissue are highly representative of proliferation index and histological grade. J Pathol 194: 349-357, 2001.
13. Merseburger AS, Kuczyk MA, Serth J, et al: Limitations of tissue microarrays in the evaluation of focal alterations of bcl-2 and p53 in whole mount derived prostate tissues. Oncol Rep 10: 223-228, 2003.
14. Torhorst J, Bucher C, Kononen J, Haas P, Zuber M, Kochli OR, Mross F, Dieterich H, Moch H, Mihatsch M, Kallioniemi OP and Sauter G: Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol 159: 2249-2256, 2001.
15. Khouja MH, Baekelandt M, Nesland JM and Holm R: The clinical importance of Ki-67, p16, p14, and p57 expression in patients with advanced ovarian carcinoma. Int J Gynecol Pathol 26: 418-425, 2007.
16. Kaplan EL and Meier P: Nonparametric estimation from incomplete observation. J Am Stat Assoc 53: 457-481, 1958.
17. Cox DR: Regression models and life tables. J R Stat Soc B 34: 187-220, 1972.
18. Sapino A, Marchio C, Senetta R, Castellano I, Macri L, Cassoni P, Ghisolfi G, Cerrato M, D'Ambrosio E and Bussolati G: Routine assessment of prognostic factors in breast cancer using a multicore tissue microarray procedure. Virchows Arch 449: 288-296, 2006.
19. Su Y, Shrubsole MJ, Ness RM, Cai Q, Kataoka N, Washington K and Zheng W: Immunohistochemical expressions of Ki-67, cyclin D1, beta-catenin, cyclooxygenase-2, and epidermal growth factor receptor in human colorectal adenoma: a validation study of tissue microarrays. Cancer Epidemiol Biomarkers Prev 15: 1719-1726, 2006.
20. Leversha MA, Fielding P, Watson S, Gosney JR and Field JK: Expression of p53, pRB, and p16 in lung tumours: a validation study on tissue microarrays. J Pathol 200: 610-619, 2003.
21. Tawfik El-Mansi M and Williams AR: Validation of tissue microarray technology using cervical adenocarcinoma and its precursors as a model system. Int J Gynecol Cancer 16: 1225-1233, 2006.
22. Kallioniemi OP, Wagner U, Kononen J and Sauter G: Tissue microarray technology for high-throughput molecular profiling of cancer. Hum Mol Genet 10: 657-662, 2001.
23. Fernebro E, Dictor M, Bendahl PO, Ferno M and Nilbert M: Evaluation of the tissue microarray technique for immunohistochemical analysis in rectal cancer. Arch Pathol Lab Med 126: 702-705, 2002.
24. Fons G, Hasibuan SM, van der Velden J and ten Kate FJ: Validation of tissue microarray technology in endometrioid cancer of the endometrium. J Clin Pathol 60: 500-503, 2007.
25. Zerkowski MP, Camp RL, Burtness BA, Rimm DL and Chung GG: Quantitative analysis of breast cancer tissue microarrays shows high cox-2 expression is associated with poor outcome. Cancer Invest 25: 19-26, 2007